反义真核细胞转化生长因子βI型受体与反义基质金属蛋白酶组织抑制因子-1联合作用对大鼠肝纤维化的影响

目的观察反义转化生长因子βI型受体(TβRI)真核表达质粒与反义基质金属蛋白酶组织抑制因子-1(TIMP-1)真核表达质粒联合作用对实验性大鼠肝纤维化的影响。方法构建大鼠反义真核细胞表达质粒,导入大鼠肝纤维化模型体内,通过I型胶原的免疫组织化学以及苦味酸-酸性品红染色观察两种反义质粒联合作用对大鼠肝纤维化的影响,用目标积分吸光度(A)值表示各实验组动物肝组织中蛋白的表达量。结果反义TβRI治疗组、反义TβRI+反义TIMP- 1治疗组、反义TIMP-1治疗组、pcDNA3.1(+)空质粒对照组、模型对照组、正常对照组TβRI蛋白的A值分别为:(2.11±0.88)×10~5、(1.06±0.57)×10~5、(3.46±1.14)×10~5、(5.66±2.54)×10~5、(5.19±1.22)×10~5和(0.38±0.27)×10~5;TIMP-1蛋白的A值分别为:(1.10±0.22)×10~5、(0.30±0.12)×10~5、(0.65±0.15)×10~5、(2.05±0.36)×10~5、(1.97±0.28)×10~5和(0.10±0.12)×10~5;I型胶原的蛋白表达的A值分别为:(4.37±1.30)×10~5、(0.90±0.32)×10~5、(3.40±0.91)×10~5、(6.90±1.61)×10~5、(7.34±1.68)×10~5和(0.41±0.21)×10~5。反义TIMP-1治疗组TIMP-1蛋白表达量显著降低(P<0.05),反义TβRI治疗组TβRI蛋白表达量显著降低(P<0.05),两种反义质粒可有效抑制相应蛋白的表达;反义TIMP-1表达质粒与反义TβRI表达质粒均可减少受损肝脏中I型胶原的沉积(P<0.05),联合应用可进一步减少受损肝脏中I型胶原的沉积(P<0.01)。在病理形态学方面的观察,反义TIMP-1表达质粒与反义TβRI表达质粒均可使受损肝脏的病理形态有一定改善,联合应用可使受损肝脏的病理形态得到进一步的改善。结论反义TIMP-1表达质粒与反义TβRI表达质粒对肝纤维化的发展均有一定的干预作用,联合作用可产生更有效的阻止作用。     

反义Ⅰ型转化生长因子β受体和反义TIMP-1联合作用对大鼠肝纤维化的抑制作用

目的观察转化生长因子βI型受体(TβRI)反义RNA联合TIMP-1反义RNA对实验性肝纤维化的影响。方法构建TβRI和TIMP-1反义RNA真核细胞表达质粒,共同导入实验性肝纤维化大鼠体内;应用免疫印记技术检测实验大鼠肝组织TIMP-1、TβRI和MMP-13蛋白表达水平。结果正常对照组、反义TβRI组、反义TIMP-1组、联合治疗组、空质粒组和模型组动物肝组织TIMP-1蛋白相对表达量分别为(23.6±2.8)、(57.96±3.8)、(62.3±2.8)、(34.2±2.8)、(279.2±29.8)和(287.3±23.7),TβRI蛋白的相对表达量分别为(56.2±2.7)、(70.5.±1.8)、(77.0±1.7)、(60.6±2.2)、(232.0±19.4)和(241.0±18.3),MMP-13蛋白相对表达量分别为(17.84±2.3)、(36.2±3.7)、(41.3±2.4)、(28.6±2.0),(127.3±1.2)和(118.5±2.5),与正常对照组及空质粒组比,反义TβRI组、联合治疗组和反义TIMP-1组TβRI、TIMP-1和MMP-13蛋白表达明显减少(P0.05),但空质粒组与模型组比无显著性差异。结论 TβRI和TIMP-1反义RNA能有效抑制TβRI、TIMP-1和MMP-13蛋白表达,两者联合应用可产生叠加效应。     

甲磺酸伊马替尼对大鼠肝纤维化及转化生长因子-β1表达的影响

目的研究甲磺酸伊马替尼在四氯化碳＋橄榄油肝纤维化模型中的抗纤维化作用及其对转化生长因子（TGF）-β1表达的影响。方法甲磺酸伊马替尼对照组大鼠（n=8）每周2次腹腔内注射橄榄油，每日予甲磺酸伊马替尼20mg／kg灌胃；正常对照组（n=8）每周2次腹腔内注射橄榄油，每日予生理盐水灌胃；肝纤维化模型组（n=12）每周2次腹腔内注射四氯化碳和橄榄油混合物，每日予生理盐水灌胃；甲磺酸伊马替尼干预组（n=12）每周2次腹腔内注射四氯化碳和橄榄油混合物，每日予甲磺酸伊马替尼20mg／kg灌胃。第8周末取动物肝中叶，Masson染色后测定胶原面积，a-SMA免疫组化染色后定量活化肝星状细胞（HSC）。反转录（RT）-PCR法测定TGF-β1、c-Ab1和金属蛋白酶组织抑制因子（TIMP）-1mRNA表达，Western印迹检测肝组织磷酸化血小板衍化生长因子（PDGF）β受体和TGF-β1蛋白表达，免疫组化检测TGF-β1、c-Ab1表达。测定肝羟脯氨酸含量。结果与肝纤维化模型组比较，甲磺酸伊马替尼干预组肝组织胶原面积和活化HSC数分别减少35％和20％[分别为（25．61±0．92）％比（16．23±1．01）％和13．10±1．21比10．52±1．33，P值均〈0．05]；TGF-β1、c-Ab1和TIMP-1的表达均较肝纤维化模型组有明显下降（0．54±0．08比0．93±0．12，0．33±0．06比0．87±0．11，0．59±0．09比0．87±0．12，P值均〈0．05）；肝组织羟脯氨酸含量（0．26±0．10）mg／g较肝纤维化模型组（0．39±0．08）mg／g有显著下降（P〈0．01）。结论甲磺酸伊马替尼可通过抑制HSC增殖和细胞外基质沉积缓解肝纤维化，并抑制TGF-β1的表达和促纤维化活性。     

反义TIMP-1表达质粒对实验性肝纤维化的影响

目的 观察反义TIMP-1真核表达质粒对实验性肝纤维化的影响.方法 运用重组DNA技术及反义技术,构建反义TIMP-1真核细胞表达质粒,经脂质体Lipofectmine2000包埋.采用腹腔注射将其导入到复合因素复制的肝纤维化大鼠模型体内,通过半定量RT-PCR,病理形态学观察及免疫组化等方法,观察反义TIMP-1表达质粒对大鼠肝纤维化的影响.结果 反义TIMP-1质粒组与肝纤维化组、空质粒组相比TIMP-1、MMP-13 mRNA及蛋白表达明显减少(P<0.05),空质粒组与肝纤维化组无显著性差异(P>0.05);正常对照组与各实验组之间的病理学分级有显著性差异(P<0.05);反义TIMP-1质粒组病理学分级较空质粒组有明显改善(P<0.05);空质粒组与肝纤维化组无显著性差异(P>0.05).结论 反义TIMP-1/pcDNA3.1( )真核细胞表达质粒使TIMP-1、MMP-13 mRNA及蛋白的表达受到抑制,反义TIMP-1表达质粒对肝纤维化有较好的改善作用,并为以后肝纤维化的基因治疗奠定基础.     

反义转化生长因子βⅠ型受体表达质粒对大鼠肝星状细胞功能的影响

目的　观察反义转化生长因子 (TGF) βⅠ型受体 (TβRⅠ )表达质粒对大鼠肝星状细胞 (HSC)增殖及细胞外基质分泌的影响。方法　双酶灌注和梯度离心法分离大鼠HSC ,将构建的反义TβRⅠ真核细胞表达质粒与 pcDNA3空质粒经脂质体转染培养活化的HSC ,通过RT PCR、Western印迹检测外源导入质粒在HSC中的表达 ,采用MTT法、3 H TdR掺入法检测细胞增殖情况 ,ELISA法检测TGF β1含量变化 ,并应用Western印迹检测HSC中Ⅰ、Ⅲ型胶原表达。结果　反义TβRⅠ真核细胞表达质粒可抑制活化HSC中TβRⅠmRNA及蛋白表达。与 pcDNA3转染组相比 ,反义TβRⅠ质粒表达可抑制HSC增殖 (P <0 .0 1) ,降低TGF β1含量 (P <0 .0 5 ) ,抑制Ⅰ、Ⅲ型胶原分泌 (P <0 .0 5 )。结论　重组反义TβRⅠ表达质粒可在HSC中获得较好表达 ,并可显著抑制HSC增殖及细胞外基质分泌。     

反义金属蛋白酶组织抑制因子-1表达质粒对实验性肝纤维化的影响

目的　观察反义金属蛋白酶组织抑制因子 1(TIMP 1)表达质粒对实验性肝纤维化的影响。方法　运用重组DNA技术构建反义TIMP 1真核细胞表达质粒 ,经与糖化多聚赖氨酸偶联后 ,尾静脉注射将其导入猪血清诱导的免疫性大鼠肝纤维化模型体内 ;通过Northern印迹法、RT PCR、Western印迹法检测外源导入基因的表达 ,并通过肝组织间质胶原酶活性和羟脯氨酸测定 ,以及肝组织Ⅰ、Ⅲ型胶原免疫组织化学与VanGieson染色观察反义TIMP 1质粒对大鼠肝纤维化的影响。结果　外源导入基因可在肝组织中获得确切表达 ,其表达可增加间质胶原酶的活性 (P <0 .0 1) ,减少羟脯氨酸含量 (P <0 .0 1) ,促进Ⅰ、Ⅲ型胶原的降解 (P <0 .0 1) ,并促进肝脏病理形态一定程度的改善 (P <0 .0 1)。结论　反义TIMP 1表达质粒对肝纤维化有较好的改善作用。     

血缘与非血缘供者异基因造血干细胞移植治疗白血病的比较研究

目的探讨血缘供者（RD）与非血缘供者（URD）造血干细胞移植（HSCT）治疗白血病的差异。方法115例白血病患者接受HLA血清学全相合异基因造血干细胞移植。流式细胞仪测定移植后1年内不同时间点患者的T细胞与B细胞重建情况。结果接受骨髓移植的RD-HSCT和URD—HSCT组WBC〉1．0×10^9／L分别为移植后（13．1±2．4）d、（16．3±3．0）d;PLT〉20×10^9／L分别为移植后（14．9±6．6）d、（20．2±7．3）d,两组WBC和PLT重建时间差异均有统计学意义（P值分别为0．003、0．042）;接受外周造血干细胞移植患者RD-HSCT和URD．HSCT组WBC〉1．0×10^9／L分别为（12．5±2．9）d、（13．1±4．1）d（P=0．488）,PLT〉20×10^9／L分另Ⅱ为（12．2±4．2）d、（15．7±7．1）d（P=0．020）。移植后1、3、6、9、12个月CD;CD;,1个月CD45RA^＋CD4^＋,3个月CD;CD;重建两组差异均有统计学意义。两组Ⅱ～Ⅳ度急、慢性移植物抗宿主病（GVHD）的发生率分别为45．5％、52．3％;45．3％、63．2％;GVHD的病死率分别为6．1％、15．9％,差异均无统计学意义。两组移植后复发率分别为18．2％、11．4％（P=0．424）。两组移植后早期感染率分别为42．4％、47．7％（P=0．696）。3年总生存率分别为（67．8±6．9）％、（61．6±7．7）％（P=0．133）,无病生存率分别为（62．3±6．9）％、（56．8±7．9）％（P=0．177）。结论URD-HSCT治疗白血病具有和RD-HSCT近似的疗效。     

甘草酸对胰腺星状细胞细胞外基质代谢调节作用的研究

目的观察甘草酸对胰腺星状细胞（PSC）合成分泌Ⅰ型胶原、基质金属蛋白酶（MMP）及其抑制物（TIMP）的影响，探讨其抗胰腺纤维化的作用机制。方法采用组织块培养法分离培养活化的PSC，培养基中添加0、1、2．5、5和10mg／ml不同剂量的甘草酸，培养24h后分别留取上清和细胞。采用放射免疫法测定上清中Ⅰ型胶原含量；明胶酶谱和反式明胶酶谱测定浓缩上清中MMP-2、MMP-9和TIMP1、TIMP-2的表达；RT-PCR测定MMP-2、MMP-9、TIMP-1、TIMP-2和I型胶原mRNA的表达。结果甘草酸可明显抑制PSC中Ⅰ型胶原含量，以5mg／ml时抑制最明显[从（52±10）ng／ml降至（35±8）ng／m1]。明胶酶谱和RT-PCR显示，PSC有MMP-2、MMP-9和TIMP-2基因和蛋白表达，而TIMP-1仅有基因表达。甘草酸可抑制MMP-2和MMP-9蛋白表达，而MMP-9基因表达未受明显抑制；甘草酸对TIMP-1和TIMP-2基因表达无明显作用，对TIMP-2蛋白的表达仅在10mg／ml浓度时有部分抑制。结论甘草酸可能通过抑制Ⅰ型胶原合成、减少MMP-2和MMP-9表达等途径抑制PSC中细胞外基质的代谢。     

马来酸罗格列酮增强过氧化物酶体增殖剂活化受体γ1基因转染抗ApoE-/-小鼠动脉粥样硬化的作用

目的探讨过氧化物酶体增殖剂活化受体（PPAR）γ活化剂马来酸罗格列酮能否增强腺病毒介导的mPPARγ1基因转染抗ApoE-／-小鼠动脉粥样硬化的作用。方法将20周龄ApoE-／-小鼠高脂饲养20周后随机分成4组（每组n=10）,即AdPPARγ1组、AdPPARγ1＋RO组（病毒干预前1周予罗格列酮4mg·kg^-1·d^-1灌胃）、AdGFP组和PBS组。转染2周后比较各组小鼠主动脉根部斑块面积均值。Movat5色套染法和油红O染色分析主动脉根部斑块成分变化。检测斑块内PPARγ、血管平滑肌细胞（SM-actin）、巨噬细胞（MOMA-2）、MMP-9／TIMP-1、CD40／CD40L和组织因子（TF）等抗原的免疫活性。结果PBS组与AdGFP组比较,各项指标差异均无统计学意义。与AdGFP组比较,AdPPARγ1组和AdPPARγ1＋RO组ApoE-／-小鼠主动脉根部斑块面积和脂质含量减少（P〈0．05）[AdGFP组、AdPPARγ1组和AdPPARγ1＋RO组病变面积均值分别为（0．98±0．17）、（0．86±0．12）、（0．79±0．15）mm^2,油红O染色阳性面积分别为（270±49）×10^3、（150±35）×10^3、（80±21）×10^3μm^2]。Movat染色法显示PBS组和AdGFP组小鼠主动脉根部斑块成分差异不显著,而AdPPARγ1组和AdPPARγ1＋RO组纤维帽较厚、弹性纤维、胶原和蛋白聚糖含量增加。与AdGFP组比较,AdPPARγ1组和AdPPARγ1＋RO组主动脉根部斑块PPARγ、SM-actin、TIMP-1抗原免疫活性增强。而MOMA-2、MMP-9、CD40／CD40L和TF抗原免疫活性减弱,其中AdPPARγ1＋RO组作用最显著。结论腺病毒介导的mPPARγ1基因转染遏制ApoE-／-小鼠动脉粥样硬化进程,促进动脉粥样硬化斑块向稳定表型转换,PPARγ活化剂马来酸罗格列酮增强上述作用。     

重型再生障碍性贫血CD4+ CD25+调节性T细胞的变化

应用流式细胞术检测重型再生障碍性贫血（SAA）患者外周血CD4^＋CD25^＋T细胞、CD4^＋CD25kighT细胞的数量。结果10例初治SAA患者外周血CD4^＋CD25^＋T细胞占CD4＋T细胞的（6．23±1．82）％,明显低于正常对照组（9.20＋2．95）％（P〈0．01）,CD4^＋CD25^highT细胞比例为（1．02±0．11）％,亦明显低于正常对照组（1．43±0．41）％;10例造血恢复SAA患者CD4^＋CD25^＋T细胞和CD4^＋CD25^hishT细胞比例分别为（8．92±1．22）％和（1．41±0．64）％,与正常对照组无明显差异（P〉0．01）。认为CD4^＋CD25^＋、CD4^＋CD25^highT细胞水平与SAA密切相关。     

反义转化生长因子βⅡ型受体表达质粒对实验性肝纤维化的影响

目的 观察反义转化生长因子βⅡ型受作(TGF βRⅡ)表达质粒对实验性肝纤维化的影响。方法 运用重组DNA技术中构建反义TGF βRⅡ真核细胞表达质粒,采用猪血清腹腔注射制备免疫性大鼠肝纤维化模型,实验动物分为肝纤维化模型组、反义TGF βRⅡ治疗组、pCDNA3对照组及正常对照组。反义TGF βRⅡ质粒和pCDNA3空质粒与糖化多聚赖氨酸偶联后经尾静脉分别导入大鼠体内,通过northern blot、RT-PCR、Western blot检测外源导入质粒在肝组织中的表达,检测血清转化生长因子β1(TGFβ1)、肝组织羟脯氨酸测定,Ⅰ、Ⅲ型胶原免疫组织化学与Van Gieson染色观察反义TGF βRⅡ质粒对大鼠肝纤维化的影响。 结果 反义TGF βRⅡ表达质粒可在肝组织中获得确切表达,其表达可使反义治疗组血清TGF β1含量下降,反义TGF βRⅡ治疗组为(23.16 ± 3.13)ng/ml,模型组为(32.96±3.79)ng/ml,F=36.73,P<0.01。肝组织羟脯氦酸含量下降,治疗组为(0.17±0.01)mg/g,模型组为(0.30±0.03)mg/g,F=15.48,P<0.01。减少了肝组织Ⅰ、Ⅲ型胶原的沉积,治疗组Ⅰ型胶原为650.26±51.51,Ⅲ型胶原为661.5 8±55.28,模型组Ⅰ型胶原为1209.44±16.60,Ⅲ型胶原为1175.14±121.44,F值分圳为69.87、70.46,P<0.01。并促进反义治疗组肝脏病理形态一定程度的改善。     

携带AFP增强子反义c-fms真核表达载体的构建及其临床意义

目的 构建人肝癌细胞中高效特异表达的反义c-fms真核表达载体,观察其对肝癌细胞生物学行为的影响。方法 采用PCR法扩增人c-fms癌基因第571位酪氨酸为中心的DNA片段,将其反向克隆人pcDNA3载体（命名pAS);将扩增的人甲胎蛋白（AFP）增强子核心区克隆人pAS（命名pAEAS)。磷酸钙法将空载体pcDNA3及反义真核表达载体pAS、pAEAS分别转导入HepG2肝癌细胞及HeLa宫颈癌细胞,观察细胞生长速度及凋亡。结果 人反义c-fms基因片段及AFP增强子核心区片段,测序结果与Genbank中登录的序列一致。导入反义基因的HepG2肝癌细胞生长速度较对照细胞明显减慢（P＜0．05）,pAEAS抑制作用较pAS强（P＜0．05,pcDNA3组、pAS组、pAEAS组HepG2肝癌细胞凋亡率分别为5．25％、14．7％、31．2％（P＜0．01）,pAEAS组细胞DNA出现梯状凋亡带。在HeLa宫颈癌细胞中,pAS及pAEAS组生长速度减慢,但二者差异无显著性（P＞0．05）,pcDNA3组、pAS组、pAEAS组细胞凋亡率分别为3．99％、8．27％、8．86％（P＜0．05）,DNA均未出现梯状凋亡带。结论 携带AFP增强子的人反义c-fms真核表达载体对AFP阳性肝癌细胞生长有选择性抑制作用,可诱导凋亡,是一种新的肝癌基因治疗方法。     

反义抑制结缔组织生长因子对实验性肝纤维化的影响

目的观察结缔组织生长因子(CTGF)反义RNA对实验性肝纤维化的影响。方法应用分子生物学技术构建CTGF反义RNA真核表达质粒,经腹腔注射入CCl4诱导的肝纤维化模型大鼠体内;通过RT-PCR、Western blot及免疫组织化学等方法检测CTGF反义RNA基因转染前后CTGF mRNA和蛋白质在肝组织中含量的变化;并通过检测肝组织中Ⅰ、Ⅲ型胶原含量的变化,观察CTGF反义RNA对大鼠肝纤维化的影响。结果转染CTGF反义RNA后,可抑制CTGF mRNA和蛋白质的表达(P<0.01),减少Ⅰ、Ⅲ型胶原的沉积(P<0.01),并在一定程度上促进肝组织的改善(P<0.01)。结论CTGF反义RNA对肝纤维化有一定的治疗作用。     

Effects of augmentation of liver regeneration recombinant plasmid on rat hepatic fibrosis

AIM: To investigate the effects of eukaryotic expression of plasmid on augmentation of liver regeneration (ALR) in rat hepatic fibrosis and to explore their mechanisms. METHODS: Ten rats were randomly selected from 50 Wistar rats as normal control group. The rest were administered intraperitoneally with porcine serum twice weekly. After 8 wk, they were randomly divided into: model control group, colchicine group (Col), first ALR group (ALR1), second ALR group (ALR2). Then colchicine ALR recombinant plasmid were used to treat them respectively. At the end of the 4th wk, rats were killed. Serum indicators were detected and histopathological changes were graded. Expression of type Ⅰ, Ⅲ, collagen and TIMP-1 were detected by immunohisto-chemistry and expression of TIMP-1 mRNA was detected by semi-quantified RT-PCR. RESULTS: The histologic examination showed that the degree of the rat hepatic fibrosis in two ALR groups was lower than those in model control group. Compared with model group, ALR significantly reduced the serum levels of ALT, AST, HA, LN, PCIII and IV (P<0.05). Immunohistochemical staining showed that expression of type Ⅰ, Ⅲ, collagen and TIMP-1 in two ALR groups was ameliorated dramatically compared with model group (I collagen: 6.94±1.42,5.80±1.66 and 10.83±3.58 in ALR1, ALR2 and model groups, respectively; Ⅲ collagen: 7.18±1.95, 4.50±1.67 and 10.25±2.61, respectively; TIMP-1: 0.39±0.05,0.20±0.06 and 0.53±0.12, respectively,P<0.05 or P<0.01). The expression level of TIMP-1 mRNA in the liver tissues was markedly decreased in two ALR groups compared with model group (TIMP-1 mRNA/β-actin: 0.89±0.08, 0.65±0.11 and 1.36±0.11 in ALR1, ALR2 and model groups respectively, P<0.01). CONCLUSION: ALR recombinant plasmid has beneficial effects on rat hepatic fibrosis by enhancing regeneration of injured liver cells and inhibiting TIMP-1 expressions.     

Inhibition on the production of collagen type Ⅰ,Ⅲ of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid

AIM: To investigate the inhibition effects on the production of collagen type Ⅰ, Ⅲ secreted by activated rat hepatic stellate cells (rHSCs) by antisense tissue inhibitors of metalloproteinase 1 (TIMP-1) recombinant plasmid through elevating interstitial collagenase activity.METHODS: rHSCs were extracted from normal rat liver by pronase and collagenase digestion and purified by centrifugal elutriation, and were cultured on plastic dishes until they were activated to a myofibroblastic phenotype after 7-10 days. RT-Nest-PCR and gene recombinant techniques were used to construct the rat antisense TIMP1 recombinant plasmids which can express in eucaryotic cells. The recombinant plasmid and the pcDNA3 empty plasmid were transfected in rHSCs by Effectene (QIAGEN)separately. Cells were selected after growing in DMEM containing 400μg/ml G418 for 2-3 weeks. Expression of exogenous gene was assessed by Northern blot, and expression of TIMP-1 in rHSCs was determined by Northern blot and Western blot. We tested the interstitial collagenase activity with FITC-labled type I collagen as substrate.Ultimately, we quantified the type Ⅰ,Ⅲ collagen byWestern blot.RESULTS: The exogenous antisense TIMP-1 recombinant plasmid could be expressed in rHSCs well, which could block the expression of TIMP-1 greatly, the ratio of TIMP-1/GAPDH was 0.67, 2.41, and 2.97 separately at mRNA level (P&lt;0.05); the ratio of TIMP-1/β-actin was 0.31, 0.98 and 1.32 separately at protein level (P&lt;0.05), It might elevate active and latent interstitial collagenase activity,the collagenase activity was 0.3049, 0.1411 and 0.1196 respectively. (P&lt;0.05), which led to promotion the degradation of type Ⅰ, Ⅲ collagen, the ratio of collagen I/β-actin was 0.63, 1.78 and 1.92 separately (P&lt;0.05); and the ratio of collagen Ⅲ/β-actin was 0.59, 1.81 and 1.98separately (P&lt;0.05).CONCLUSION: These data shows that the antisense TIMP-1 recombinant plasmid has the inhibitory effects on the production of type Ⅰ,Ⅲ collagens secreted by activated rHSCs in vitro. It could be a novel method to reverse hepatic fibrosis in the future.     

Blockage of transforming growth factor β receptors prevents progression of pig serum-induced rat liver fibrosis

AIM: To test the hypothesis that introduction of antisense TβR Ⅰ and TβR Ⅱ eukaryotic expressing plasmids into a rat model of immunologically induced liver fibrosis might block the action of TGF-β1 and halt the progression of liver fibrosis. METHODS: RT-Nest-PCR and gene recombination techniques were used to construct rat antisense TβR Ⅰ and TβR Ⅱ recombinant plasmids which could be expressed in eukaryotic cells. The recombinant plasmids and empty vector (pcDNA3) were encapsulated by glycosyl-poly-L-lysine and then transducted into rats of pig serum-induced liver fibrosis model. Expression of exogenously transfected gene was assessed by Northern blot, and hepatic expressions of TβR Ⅰ and TβR Ⅱ were evaluated by RT-PCR and Western blot.We also performed ELISA for serum TGF-β1, hydroxyproline of hepatic tissues, immunohistochemistry for collagen types Ⅰ and Ⅲ, and VG staining for pathological study of the liver tissues. RESULTS: The exogenous antisense TβR Ⅰ and TβR Ⅱ plasmids could be well expressed in vivo, and block mRNA and protein expression of TβR Ⅰ and TβR Ⅱ in the fibrotic liver at the level of mRNA respectively. These exogenous plasmid expressions reduced the level of TGF-β1 (antisense TβR Ⅰ group 23.998+3.045 ng/mL, antisense TβR Ⅱ group 23.156+3.131 ng/mL, disease control group 32.960+3.789 ng/mL; F-=-38.19, 36.73, P&lt;0.01). Compared with disease control group, the contents of hepatic hydroxyproline (antisense TβR Ⅰ group 0.169+0.015 mg/g liver, antisense TβR Ⅱ group 0.167+0.009 mg/g liver, disease control group 0.296+0.026 mg/g liver; F=14.39, 15.48, P&lt;0.01) and the deposition of collagen types Ⅰ and Ⅲ decreased in the two antisense treatment groups(antisense TβR Ⅰ group, collagen type Ⅰ 669.90+50.67, collagen type Ⅲ 657.29+49.48; antisense TβR Ⅱ group, collagen type Ⅰ 650.26+51.51, collagen type Ⅲ 661.58+55.28; disease control group, collagen type I 1209.44+116.60, collagen type Ⅲ 1175.14+121.44; F=15.48 to 74.89, P&lt;0.01). Their expression also improved the pathologic classification of liver fibrosis models (compared with disease control group, X^2=17.14, 17.24, P&lt;0.01). No difference was found in the level of TGF-β1, the contents of hepatic hydroxyproline and collagen types Ⅰ and Ⅲ and pathologic grade between pcDNA3 control group and disease control group or between the two antisense treatment groups (F=0.11 to1.06, X^2=0.13 to 0.16, P&gt;0.05). CONCLUSION: Antisense TβR Ⅰ and TβR Ⅱ recombinant plasmids have certain reverse effects on liver fibrosis and can be used as possible candidates for gene therapy.     

Blockage of transforming growth factor β receptors prevents progression of pig serum-induced rat liver fibrosis

AIM: To test the hypothesis that introduction of antisense TβR Ⅰ and TβR Ⅱ eukaryotic expressing plasmids into a rat model of immunologically induced liver fibrosis might block the action of TGF-β1 and halt the progression of liver fibrosis.METHODS: RT-Nest-PCR and gene recombination techniques were used to construct rat antisense TβR Ⅰ and TβR Ⅱ recombinant plasmids which could be expressed in eukaryotic cells. The recombinant plasmids and empty vector (pcDNA3) were encapsulated by glycosyl-poly-Llysine and then transducted into rats of pig serum-induced liver fibrosis model. Expression of exogenously transfected gene was assessed by Northern blot, and hepatic expressions of TβR Ⅰ and TβR Ⅱ were evaluated by RTPCR and Western blot. We also performed ELISA for serum TGF-β1, hydroxyproline of hepatic tissues, immunohistochemistry for collagen types Ⅰ and Ⅲ, and VG staining for pathological study of the liver tissues.RESULTS: The exogenous antisense TβR Ⅰ and TβR Ⅱ plasmids could be well expressed in vivo, and block mRNA and protein expression of TβR Ⅰ and TβR Ⅱ in the fibrotic liver at the level of mRNA respectively. These exogenous plasmid expressions reduced the level of TGF-β1(antisense TβR Ⅰ group 23.998±3.045 ng/mL, antisense TβR Ⅱ group 23.156±3.131 ng/mL, disease control group 32.960±3.789 ng/mL; F=38.19, 36.73, P＜0.01). Compared with disease control group, the contents of hepatic hydroxyproline (antisense TβR Ⅰ group 0.169±0.015 mg/g liver, antisense TβR Ⅱ group 0.167±0.009 mg/g liver,disease control group 0.296±0.026 mg/g liver; F=14.39,15.48, P＜0.01) and the deposition of collagen types Ⅰ and Ⅲ decreased in the two antisense treatment groups (antisense TβR Ⅰ group, collagen type Ⅰ 669.90±50.67,collagen type Ⅲ 657.29±49.48; antisense TβR Ⅱ group,collagen type Ⅰ 650.26±51.51, collagen type Ⅲ 661.58±55.28;disease control group, collagen type Ⅰ 1209.44±116.60,collagen type Ⅲ 1175.14±121.44; F=15.48 to 74.89, P＜0.01).Their expression also improved the pathologic classification of liver fibrosis models (compared with disease control group, x2=17.14, 17.24, P＜0.01). No difference was found in the level of TGF-β1, the contents of hepatic hydroxyproline and collagen types Ⅰ and Ⅲ and pathologic grade between pcDNA3 control group and disease control group or between the two antisense treatment groups (F =0.11 to 1.06, x2=0.13 to 0.16, P＞0.05).CONCLUSION: Antisense TβR Ⅰ and TβR Ⅱ recombinant plasmids have certain reverse effects on liver fibrosis and can be used as possible candidates for gene therapy.     

Inhibition on the production of collagen type Ⅰ, Ⅲ of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid

AIM: To investigate the inhibition effects on the productionof collagen type I, Ⅲ secreted by activated rat hepatic stellatecells (rHSCs) by antisense tissue inhibitors of metalloproteinase1 (TIMP-1) recombinant plasmid through elevating interstitialcollagenase activity.METHODS: rHSCs were extracted from normal rat liverby pronase and collagenase digestion and purified bycentrifugal elutriation, and were cultured on plastic dishesuntil they were activated to a myofibroblastic phenotypeafter 7-10 days. RT-Nest-PCR and gene recombinanttechniques were used to construct the rat antisense TIMP-1 recombinant plasmids which can express in eucaryoticcells. The recombinant plasmid and the pcDNA3 emptyplasmid were transfected in rHSCs by Effectene (QIAGEN)separately. Cells were selected after growing in DMEMcontaining 400 μg/ml G418 for 2-3 weeks. Expression ofexogenous gene was assessed by Northern blot, andexpression oflIMP-1 in rHSCs was determined by Northernblot and Western blot. We tested the interstitial collagenaseactivity with FITC-labled type I collagen as substrate.Ultimately, we quantified the type Ⅰ, Ⅲ collagen byWestern blot.RESULTS: The exogenous antisense TIMP-1 recombinantplasmid could be expressed in rHSCs well, which couldblock the expression of TIMP-1 greatly, the ratio of TIMP-1/GAPDH was 0.67, 2.41, and 2.97 separately at mRNAlevel (P＜0.05); the ratio of TIMP-1/β-actin was 0.31, 0.98and 1.32 separately at protein level (P＜0.05); It mightelevate active and latent interstitial collagenase activity,the collagenase activity was 0.3049, 0.1411 and 0.1196respectively. (P＜0.05), which led to promotion thedegradation of type Ⅰ, Ⅲ collagen, the ratio of collagen I/β-actin was 0.63, 1.78 and 1.92 separately (P＜0.05); andthe ratio of collagen Ⅲ/β-actin was 0.59, 1.81 and 1.98separately (P＜0.05).CONCLUSION: These data shows that the antisense TIMP-1 recombinant plasmid has the inhibitory effects on theproduction of type Ⅰ, Ⅲ collagens secreted by activatedrHSCs in vitro. It could be a novel method to reverse hepaticfibrosis in the future.     

TAGLN真核表达载体pcDNA6.2/EmGFP-Bsd/V5-TAG-LN-mut及稳定转染细胞株的构建

目的:构建携tagln基因的真核表达载体,建立稳定转染该质粒的人结肠癌细胞株RKO并鉴定.方法:通过Gateway克隆技术,使用pOTB7-TAGLN-mut与pDONR221进行BP重组反应产生入门克隆,再与pcDNA6.2/EmGFP-BsdV5-DEST空载体进行LR重组反应,生成目的质粒pcDNA6.2/EmGFP-Bsd/V5-TAGLN-mut通过测序验证目的质粒的插入序列.将携带tagln的真核表达载体和对照质粒稳定转染至人结肠癌细胞株RKO.通过实时荧光定量PCR和免疫印迹检测tagln的mRNA和蛋白表达水平.通过细胞侵袭实验了解transgelin在结肠癌细胞RKO中的作用.结果:携带tagln的真核表达载体测序分析显示插入序列及位点正确;实时荧光定量PCR及免疫印迹结果显示,稳定转染重组目的质粒的细胞株(RKO-TAGLN细胞)中tagln的表达水平与转染对照质粒的细胞株(RKO-CTRL细胞)及野生型RKO细胞相比明显上调,差异具有统计学意义(mRNA相对表达水平分别为45.58±12.79、1.32±0.43和1,P<0.01;蛋白质灰度定量值为1.69±0.04、0.29±0.05和0.29±0.04,P<0.01).细胞侵袭实验提示,RKO-TAGLN细胞较RKO-CTRL细胞的侵袭能力提高(161.76%±61.18%,P<0.01).结论:成功构建携tagln基因的真核表达载体并建立过表达transgelin的稳定细胞株和对照细胞株,为研究transgelin在结肠癌中的作用奠定基础.     

分泌性内皮抑制素真核质粒治疗小鼠肝癌的初步研究

目的 构建并表达分泌性内皮抑制素真核表达质粒,以此对肝癌进行基因治疗。方法 人工合成Ig κ信号肽序列,和内皮抑制素编码序列一起克隆入pcDNA3.1质粒。重组质粒转染上清液作用于ECV304内皮细胞,MTT法检测内皮细胞的增殖。局部注射重组质粒治疗接种在小鼠腿部肌肉内的H_(22)肝癌瘤株,疗程结束后解剖称取瘤重。结果 构建的内皮抑制素真核表达质粒转染上清液可以抑制内皮细胞的增殖抑制率为29.2％。经质粒裸DNA注射治疗后,治疗组瘤重[(1.34±0.96)g]比空载体组[(2.70±0.82)g]和生理盐水组[(3.73±1.41)g]明显减小(P<0.05)。结论 分泌性内皮抑制素真核表达质粒用于H_(22)肝癌的基因治疗有一定效果。